A pilot validation in 10 European Union Member States of a point prevalence survey of healthcare-associated infections and antimicrobial use in acute hospitals in Europe, 2011
We present a pilot validation study performed on 10 European Union (EU) Member States, of a point prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in Europe in 2011 involving 29 EU/European Economic Area (EEA) countries and Croatia. A total of 20 acute hospita...
Gespeichert in:
Veröffentlicht in: | Euro surveillance : bulletin européen sur les maladies transmissibles 2015-02, Vol.20 (8), p.1 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 8 |
container_start_page | 1 |
container_title | Euro surveillance : bulletin européen sur les maladies transmissibles |
container_volume | 20 |
creator | Reilly, J S Price, L Godwin, J Cairns, S Hopkins, S Cookson, B Malcolm, W Hughes, G Lyytikainen, O Coignard, B Hansen, S Suetens, C |
description | We present a pilot validation study performed on 10 European Union (EU) Member States, of a point prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in Europe in 2011 involving 29 EU/European Economic Area (EEA) countries and Croatia. A total of 20 acute hospitals and 1,950 patient records were included in the pilot study, which consisted of validation and inter-rater reliability (IRR) testing using an in-hospital observation approach. In the validation, a sensitivity of 83% (95% confidence interval (CI): 79–87%) and a specificity of 98% (95% CI: 98–99%) were found for HAIs. The level of agreement between the primary PPS and validation results were very good for HAIs overall (Cohen’s κappa (κ):0.81) and across all the types of HAIs (range: 0.83 for bloodstream infections to 1.00 for lower respiratory tract infections). Antimicrobial use had a sensitivity of 94% (95% CI: 93–95%) and specificity of 97% (95% CI: 96–98%) with a very good level of agreement (κ:0.91). Agreement on other demographic items ranged from moderate to very good (κ: 0.57–0.95): age (κ:0.95), sex (κ: 0.93), specialty of physician (κ: 0.87) and McCabe score (κ: 0.57). IRR showed a very good level of agreement (κ: 0.92) for both the presence of HAIs and antimicrobial use. This pilot study suggested valid and reliable reporting of HAIs and antimicrobial use in the PPS dataset. The lower level of sensitivity with respect to reporting of HAIs reinforces the importance of training data collectors and including validation studies as part of a PPS in order for the burden of HAIs to be better estimated. |
doi_str_mv | 10.2807/1560-7917.ES2015.20.8.21045 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1661332681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1661332681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3875-2bbcb9df4ddb5afa971757a722867b8f07e7a5fe9709a7fdcbed063a43a9de023</originalsourceid><addsrcrecordid>eNpdUc1q3jAQNKWl-WlfoQhy6aF2JdmybHoK4WtTSMghyVmspRWfgm25khzIU_UVK_dLQ8lBrJid2dlliuKM0Yp3VH5loqWl7JmsdrecMlFxWnUVZ7QRb4rjl-7b__5HxUmMD5Q2Ne35--KIC9nwpm6Oi9_nZHGjT-QRRmcgOT8TNxNGyW4NfkGYyf28gdc4DRjIbYKEkXhLgCzezYksAbMWZ40kruERn7bmHmFMew0BS4jRa5dVJg-2qDeLSGA2-SU3OR384GAka8TNGfSakOx9XFyCMW7QYZMvJB_LPhTvbIbx43M9Le6_7-4uLsurmx8_L86vSl13UpR8GPTQG9sYMwiw0EsmhQTJedfKobNUogRhsZe0B2mNHtDQtoamht4g5fVp8fkwdwn-14oxqclFjeMIM_o1Kta2rK5527FMPXtFffBrmPN2Gyvv3AtGM-vbgZXvjTGgVUtwE4QnxajaclVbWmpLSx1yVZyqTv3NNas_PXusw4TmRfsvyPoPy52g8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1660119510</pqid></control><display><type>article</type><title>A pilot validation in 10 European Union Member States of a point prevalence survey of healthcare-associated infections and antimicrobial use in acute hospitals in Europe, 2011</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Reilly, J S ; Price, L ; Godwin, J ; Cairns, S ; Hopkins, S ; Cookson, B ; Malcolm, W ; Hughes, G ; Lyytikainen, O ; Coignard, B ; Hansen, S ; Suetens, C</creator><creatorcontrib>Reilly, J S ; Price, L ; Godwin, J ; Cairns, S ; Hopkins, S ; Cookson, B ; Malcolm, W ; Hughes, G ; Lyytikainen, O ; Coignard, B ; Hansen, S ; Suetens, C ; National Participants in the ECDC pilot validation study</creatorcontrib><description>We present a pilot validation study performed on 10 European Union (EU) Member States, of a point prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in Europe in 2011 involving 29 EU/European Economic Area (EEA) countries and Croatia. A total of 20 acute hospitals and 1,950 patient records were included in the pilot study, which consisted of validation and inter-rater reliability (IRR) testing using an in-hospital observation approach. In the validation, a sensitivity of 83% (95% confidence interval (CI): 79–87%) and a specificity of 98% (95% CI: 98–99%) were found for HAIs. The level of agreement between the primary PPS and validation results were very good for HAIs overall (Cohen’s κappa (κ):0.81) and across all the types of HAIs (range: 0.83 for bloodstream infections to 1.00 for lower respiratory tract infections). Antimicrobial use had a sensitivity of 94% (95% CI: 93–95%) and specificity of 97% (95% CI: 96–98%) with a very good level of agreement (κ:0.91). Agreement on other demographic items ranged from moderate to very good (κ: 0.57–0.95): age (κ:0.95), sex (κ: 0.93), specialty of physician (κ: 0.87) and McCabe score (κ: 0.57). IRR showed a very good level of agreement (κ: 0.92) for both the presence of HAIs and antimicrobial use. This pilot study suggested valid and reliable reporting of HAIs and antimicrobial use in the PPS dataset. The lower level of sensitivity with respect to reporting of HAIs reinforces the importance of training data collectors and including validation studies as part of a PPS in order for the burden of HAIs to be better estimated.</description><identifier>ISSN: 1560-7917</identifier><identifier>ISSN: 1025-496X</identifier><identifier>EISSN: 1560-7917</identifier><identifier>DOI: 10.2807/1560-7917.ES2015.20.8.21045</identifier><identifier>PMID: 25742434</identifier><language>eng</language><publisher>Sweden: Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</publisher><subject>Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; Antimicrobial agents ; Bacterial Infections - drug therapy ; Bacterial Infections - epidemiology ; Bacterial Infections - etiology ; Confidence intervals ; Croatia - epidemiology ; Cross Infection - drug therapy ; Cross Infection - epidemiology ; Cross Infection - etiology ; Cross Infection - microbiology ; Demographics ; Drug Prescriptions - statistics & numerical data ; Drug Resistance, Microbial ; Drug Utilization Review - methods ; Drug Utilization Review - statistics & numerical data ; EU membership ; Europe - epidemiology ; European Union ; Female ; Health Surveys ; Hospitals - statistics & numerical data ; Humans ; Male ; Middle Aged ; Nosocomial infections ; Pilot Projects ; Prevalence ; Reproducibility of Results ; Sensitivity and Specificity ; Validation studies</subject><ispartof>Euro surveillance : bulletin européen sur les maladies transmissibles, 2015-02, Vol.20 (8), p.1</ispartof><rights>Copyright Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) Feb 26, 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3875-2bbcb9df4ddb5afa971757a722867b8f07e7a5fe9709a7fdcbed063a43a9de023</citedby><cites>FETCH-LOGICAL-c3875-2bbcb9df4ddb5afa971757a722867b8f07e7a5fe9709a7fdcbed063a43a9de023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25742434$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reilly, J S</creatorcontrib><creatorcontrib>Price, L</creatorcontrib><creatorcontrib>Godwin, J</creatorcontrib><creatorcontrib>Cairns, S</creatorcontrib><creatorcontrib>Hopkins, S</creatorcontrib><creatorcontrib>Cookson, B</creatorcontrib><creatorcontrib>Malcolm, W</creatorcontrib><creatorcontrib>Hughes, G</creatorcontrib><creatorcontrib>Lyytikainen, O</creatorcontrib><creatorcontrib>Coignard, B</creatorcontrib><creatorcontrib>Hansen, S</creatorcontrib><creatorcontrib>Suetens, C</creatorcontrib><creatorcontrib>National Participants in the ECDC pilot validation study</creatorcontrib><title>A pilot validation in 10 European Union Member States of a point prevalence survey of healthcare-associated infections and antimicrobial use in acute hospitals in Europe, 2011</title><title>Euro surveillance : bulletin européen sur les maladies transmissibles</title><addtitle>Euro Surveill</addtitle><description>We present a pilot validation study performed on 10 European Union (EU) Member States, of a point prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in Europe in 2011 involving 29 EU/European Economic Area (EEA) countries and Croatia. A total of 20 acute hospitals and 1,950 patient records were included in the pilot study, which consisted of validation and inter-rater reliability (IRR) testing using an in-hospital observation approach. In the validation, a sensitivity of 83% (95% confidence interval (CI): 79–87%) and a specificity of 98% (95% CI: 98–99%) were found for HAIs. The level of agreement between the primary PPS and validation results were very good for HAIs overall (Cohen’s κappa (κ):0.81) and across all the types of HAIs (range: 0.83 for bloodstream infections to 1.00 for lower respiratory tract infections). Antimicrobial use had a sensitivity of 94% (95% CI: 93–95%) and specificity of 97% (95% CI: 96–98%) with a very good level of agreement (κ:0.91). Agreement on other demographic items ranged from moderate to very good (κ: 0.57–0.95): age (κ:0.95), sex (κ: 0.93), specialty of physician (κ: 0.87) and McCabe score (κ: 0.57). IRR showed a very good level of agreement (κ: 0.92) for both the presence of HAIs and antimicrobial use. This pilot study suggested valid and reliable reporting of HAIs and antimicrobial use in the PPS dataset. The lower level of sensitivity with respect to reporting of HAIs reinforces the importance of training data collectors and including validation studies as part of a PPS in order for the burden of HAIs to be better estimated.</description><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antimicrobial agents</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - epidemiology</subject><subject>Bacterial Infections - etiology</subject><subject>Confidence intervals</subject><subject>Croatia - epidemiology</subject><subject>Cross Infection - drug therapy</subject><subject>Cross Infection - epidemiology</subject><subject>Cross Infection - etiology</subject><subject>Cross Infection - microbiology</subject><subject>Demographics</subject><subject>Drug Prescriptions - statistics & numerical data</subject><subject>Drug Resistance, Microbial</subject><subject>Drug Utilization Review - methods</subject><subject>Drug Utilization Review - statistics & numerical data</subject><subject>EU membership</subject><subject>Europe - epidemiology</subject><subject>European Union</subject><subject>Female</subject><subject>Health Surveys</subject><subject>Hospitals - statistics & numerical data</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nosocomial infections</subject><subject>Pilot Projects</subject><subject>Prevalence</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Validation studies</subject><issn>1560-7917</issn><issn>1025-496X</issn><issn>1560-7917</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUc1q3jAQNKWl-WlfoQhy6aF2JdmybHoK4WtTSMghyVmspRWfgm25khzIU_UVK_dLQ8lBrJid2dlliuKM0Yp3VH5loqWl7JmsdrecMlFxWnUVZ7QRb4rjl-7b__5HxUmMD5Q2Ne35--KIC9nwpm6Oi9_nZHGjT-QRRmcgOT8TNxNGyW4NfkGYyf28gdc4DRjIbYKEkXhLgCzezYksAbMWZ40kruERn7bmHmFMew0BS4jRa5dVJg-2qDeLSGA2-SU3OR384GAka8TNGfSakOx9XFyCMW7QYZMvJB_LPhTvbIbx43M9Le6_7-4uLsurmx8_L86vSl13UpR8GPTQG9sYMwiw0EsmhQTJedfKobNUogRhsZe0B2mNHtDQtoamht4g5fVp8fkwdwn-14oxqclFjeMIM_o1Kta2rK5527FMPXtFffBrmPN2Gyvv3AtGM-vbgZXvjTGgVUtwE4QnxajaclVbWmpLSx1yVZyqTv3NNas_PXusw4TmRfsvyPoPy52g8Q</recordid><startdate>20150226</startdate><enddate>20150226</enddate><creator>Reilly, J S</creator><creator>Price, L</creator><creator>Godwin, J</creator><creator>Cairns, S</creator><creator>Hopkins, S</creator><creator>Cookson, B</creator><creator>Malcolm, W</creator><creator>Hughes, G</creator><creator>Lyytikainen, O</creator><creator>Coignard, B</creator><creator>Hansen, S</creator><creator>Suetens, C</creator><general>Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150226</creationdate><title>A pilot validation in 10 European Union Member States of a point prevalence survey of healthcare-associated infections and antimicrobial use in acute hospitals in Europe, 2011</title><author>Reilly, J S ; Price, L ; Godwin, J ; Cairns, S ; Hopkins, S ; Cookson, B ; Malcolm, W ; Hughes, G ; Lyytikainen, O ; Coignard, B ; Hansen, S ; Suetens, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3875-2bbcb9df4ddb5afa971757a722867b8f07e7a5fe9709a7fdcbed063a43a9de023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antimicrobial agents</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - epidemiology</topic><topic>Bacterial Infections - etiology</topic><topic>Confidence intervals</topic><topic>Croatia - epidemiology</topic><topic>Cross Infection - drug therapy</topic><topic>Cross Infection - epidemiology</topic><topic>Cross Infection - etiology</topic><topic>Cross Infection - microbiology</topic><topic>Demographics</topic><topic>Drug Prescriptions - statistics & numerical data</topic><topic>Drug Resistance, Microbial</topic><topic>Drug Utilization Review - methods</topic><topic>Drug Utilization Review - statistics & numerical data</topic><topic>EU membership</topic><topic>Europe - epidemiology</topic><topic>European Union</topic><topic>Female</topic><topic>Health Surveys</topic><topic>Hospitals - statistics & numerical data</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nosocomial infections</topic><topic>Pilot Projects</topic><topic>Prevalence</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Validation studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reilly, J S</creatorcontrib><creatorcontrib>Price, L</creatorcontrib><creatorcontrib>Godwin, J</creatorcontrib><creatorcontrib>Cairns, S</creatorcontrib><creatorcontrib>Hopkins, S</creatorcontrib><creatorcontrib>Cookson, B</creatorcontrib><creatorcontrib>Malcolm, W</creatorcontrib><creatorcontrib>Hughes, G</creatorcontrib><creatorcontrib>Lyytikainen, O</creatorcontrib><creatorcontrib>Coignard, B</creatorcontrib><creatorcontrib>Hansen, S</creatorcontrib><creatorcontrib>Suetens, C</creatorcontrib><creatorcontrib>National Participants in the ECDC pilot validation study</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reilly, J S</au><au>Price, L</au><au>Godwin, J</au><au>Cairns, S</au><au>Hopkins, S</au><au>Cookson, B</au><au>Malcolm, W</au><au>Hughes, G</au><au>Lyytikainen, O</au><au>Coignard, B</au><au>Hansen, S</au><au>Suetens, C</au><aucorp>National Participants in the ECDC pilot validation study</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A pilot validation in 10 European Union Member States of a point prevalence survey of healthcare-associated infections and antimicrobial use in acute hospitals in Europe, 2011</atitle><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle><addtitle>Euro Surveill</addtitle><date>2015-02-26</date><risdate>2015</risdate><volume>20</volume><issue>8</issue><spage>1</spage><pages>1-</pages><issn>1560-7917</issn><issn>1025-496X</issn><eissn>1560-7917</eissn><abstract>We present a pilot validation study performed on 10 European Union (EU) Member States, of a point prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in Europe in 2011 involving 29 EU/European Economic Area (EEA) countries and Croatia. A total of 20 acute hospitals and 1,950 patient records were included in the pilot study, which consisted of validation and inter-rater reliability (IRR) testing using an in-hospital observation approach. In the validation, a sensitivity of 83% (95% confidence interval (CI): 79–87%) and a specificity of 98% (95% CI: 98–99%) were found for HAIs. The level of agreement between the primary PPS and validation results were very good for HAIs overall (Cohen’s κappa (κ):0.81) and across all the types of HAIs (range: 0.83 for bloodstream infections to 1.00 for lower respiratory tract infections). Antimicrobial use had a sensitivity of 94% (95% CI: 93–95%) and specificity of 97% (95% CI: 96–98%) with a very good level of agreement (κ:0.91). Agreement on other demographic items ranged from moderate to very good (κ: 0.57–0.95): age (κ:0.95), sex (κ: 0.93), specialty of physician (κ: 0.87) and McCabe score (κ: 0.57). IRR showed a very good level of agreement (κ: 0.92) for both the presence of HAIs and antimicrobial use. This pilot study suggested valid and reliable reporting of HAIs and antimicrobial use in the PPS dataset. The lower level of sensitivity with respect to reporting of HAIs reinforces the importance of training data collectors and including validation studies as part of a PPS in order for the burden of HAIs to be better estimated.</abstract><cop>Sweden</cop><pub>Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</pub><pmid>25742434</pmid><doi>10.2807/1560-7917.ES2015.20.8.21045</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1560-7917 |
ispartof | Euro surveillance : bulletin européen sur les maladies transmissibles, 2015-02, Vol.20 (8), p.1 |
issn | 1560-7917 1025-496X 1560-7917 |
language | eng |
recordid | cdi_proquest_miscellaneous_1661332681 |
source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Antimicrobial agents Bacterial Infections - drug therapy Bacterial Infections - epidemiology Bacterial Infections - etiology Confidence intervals Croatia - epidemiology Cross Infection - drug therapy Cross Infection - epidemiology Cross Infection - etiology Cross Infection - microbiology Demographics Drug Prescriptions - statistics & numerical data Drug Resistance, Microbial Drug Utilization Review - methods Drug Utilization Review - statistics & numerical data EU membership Europe - epidemiology European Union Female Health Surveys Hospitals - statistics & numerical data Humans Male Middle Aged Nosocomial infections Pilot Projects Prevalence Reproducibility of Results Sensitivity and Specificity Validation studies |
title | A pilot validation in 10 European Union Member States of a point prevalence survey of healthcare-associated infections and antimicrobial use in acute hospitals in Europe, 2011 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T09%3A12%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20pilot%20validation%20in%2010%20European%20Union%20Member%20States%20of%20a%20point%20prevalence%20survey%20of%20healthcare-associated%20infections%20and%20antimicrobial%20use%20in%20acute%20hospitals%20in%20Europe,%202011&rft.jtitle=Euro%20surveillance%20:%20bulletin%20europ%C3%A9en%20sur%20les%20maladies%20transmissibles&rft.au=Reilly,%20J%20S&rft.aucorp=National%20Participants%20in%20the%20ECDC%20pilot%20validation%20study&rft.date=2015-02-26&rft.volume=20&rft.issue=8&rft.spage=1&rft.pages=1-&rft.issn=1560-7917&rft.eissn=1560-7917&rft_id=info:doi/10.2807/1560-7917.ES2015.20.8.21045&rft_dat=%3Cproquest_cross%3E1661332681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1660119510&rft_id=info:pmid/25742434&rfr_iscdi=true |